Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer : ATHENA study-France
The efficacy of the combination bevacizumab-chemotherapy in the first-line treatment of metastatic breast cancer (mBC) was demonstrated in several randomized clinical trials. However, limited safety data is available in daily medical practice. ATHENA is an international phase-IIIb study conducted in 2,251 patients with locally advanced or mBC, treated in first-line with bevacizumab combined with taxanes-based chemotherapy. The primary objective is safety assessment. In France, 365 patients were included. Their median age was 56 years (24-93 years) and ECOG performance status was 0 or 1 in 93.9% of patients. Bevacizumab was essentially combined with a taxanes monotherapy: docetaxel (37.3%) or paclitaxel (28.8%) or taxanes-based combination therapy (9.4%). The most frequent grade superior or equal to 3 adverse event (AE) was neutropenia (34.5%). Grade superior or equal to 3 AEs of special interest related to bevacizumab were arterial and venous thromboembolism (5.1%), high blood pressure (4.2%), proteinuria (2.3%) and hemorrhage (2%). Median time to progression was 9.5 months (95% CI: 8.8-10.4). The safety profile and the efficacy of the combination bevacizumab-taxanes in a population more representative of daily oncology practice in France are comparable to those reported in clinical trials in mBC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2012 |
|---|---|
| Erschienen: |
2012 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:99 |
|---|---|
| Enthalten in: |
Bulletin du cancer - 99(2012), 6 vom: 27. Juni, Seite 609-18 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Tolérance et efficacité du bévacizumab en association aux taxanes en première ligne dans le cancer du sein métastatique : étude ATHENA-France |
|---|
| Beteiligte Personen: |
Hardy-Bessard, Anne-Claire [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
15H5577CQD |
|---|
| Anmerkungen: |
Date Completed 21.08.2012 Date Revised 01.12.2018 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1684/bdc.2012.1586 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM218340621 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM218340621 | ||
| 003 | DE-627 | ||
| 005 | 20231224040156.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2012 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1684/bdc.2012.1586 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0727.xml |
| 035 | |a (DE-627)NLM218340621 | ||
| 035 | |a (NLM)22665515 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Hardy-Bessard, Anne-Claire |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer |b ATHENA study-France |
| 246 | 3 | 3 | |a Tolérance et efficacité du bévacizumab en association aux taxanes en première ligne dans le cancer du sein métastatique : étude ATHENA-France |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.08.2012 | ||
| 500 | |a Date Revised 01.12.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The efficacy of the combination bevacizumab-chemotherapy in the first-line treatment of metastatic breast cancer (mBC) was demonstrated in several randomized clinical trials. However, limited safety data is available in daily medical practice. ATHENA is an international phase-IIIb study conducted in 2,251 patients with locally advanced or mBC, treated in first-line with bevacizumab combined with taxanes-based chemotherapy. The primary objective is safety assessment. In France, 365 patients were included. Their median age was 56 years (24-93 years) and ECOG performance status was 0 or 1 in 93.9% of patients. Bevacizumab was essentially combined with a taxanes monotherapy: docetaxel (37.3%) or paclitaxel (28.8%) or taxanes-based combination therapy (9.4%). The most frequent grade superior or equal to 3 adverse event (AE) was neutropenia (34.5%). Grade superior or equal to 3 AEs of special interest related to bevacizumab were arterial and venous thromboembolism (5.1%), high blood pressure (4.2%), proteinuria (2.3%) and hemorrhage (2%). Median time to progression was 9.5 months (95% CI: 8.8-10.4). The safety profile and the efficacy of the combination bevacizumab-taxanes in a population more representative of daily oncology practice in France are comparable to those reported in clinical trials in mBC | ||
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 7 | |a Angiogenesis Inhibitors |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Taxoids |2 NLM | |
| 650 | 7 | |a Docetaxel |2 NLM | |
| 650 | 7 | |a 15H5577CQD |2 NLM | |
| 650 | 7 | |a Bevacizumab |2 NLM | |
| 650 | 7 | |a 2S9ZZM9Q9V |2 NLM | |
| 650 | 7 | |a Paclitaxel |2 NLM | |
| 650 | 7 | |a P88XT4IS4D |2 NLM | |
| 700 | 1 | |a Delva, Rémy |e verfasserin |4 aut | |
| 700 | 1 | |a Pivot, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Espié, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Dalenc, Florence |e verfasserin |4 aut | |
| 700 | 1 | |a Coulon Sfairi, Marie-Aude |e verfasserin |4 aut | |
| 700 | 1 | |a Monnier, Alain |e verfasserin |4 aut | |
| 700 | 1 | |a Serin, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Veyret, Corinne |e verfasserin |4 aut | |
| 700 | 1 | |a Lortholary, Alain |e verfasserin |4 aut | |
| 700 | 1 | |a Pavlyuk, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Kockler, Leila |e verfasserin |4 aut | |
| 700 | 1 | |a Pierga, Jean-Yves |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bulletin du cancer |d 1966 |g 99(2012), 6 vom: 27. Juni, Seite 609-18 |w (DE-627)NLM000155853 |x 1769-6917 |7 nnns |
| 773 | 1 | 8 | |g volume:99 |g year:2012 |g number:6 |g day:27 |g month:06 |g pages:609-18 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1684/bdc.2012.1586 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 99 |j 2012 |e 6 |b 27 |c 06 |h 609-18 | ||